Antti Mustonen

I am an Assistant Professor of Psychiatry at Tampere University and a practicing addiction psychiatrist at Seinäjoki Central Hospital. I also collaborate closely with the Department of Clinical Neuroscience at Karolinska Institutet on joint research projects.

My research focuses on the relationship between youth cannabis use and mental health outcomes, particularly how early cannabis exposure influences the development and prognosis of psychiatric disorders, as well as the identification of effective treatments for such conditions.

I co-lead projects examining the long-term outcomes and real-world effectiveness of treatments for severe mental and substance use disorders, with a special emphasis on cannabis-related conditions. These studies leverage national health registers and large birth cohort data to explore clinical trajectories and treatment outcomes in real-world settings.

I collaborate with people with lived experience of mental illness and substance use. By integrating clinical evidence with experiential knowledge and drawing on international, multidisciplinary collaboration, my goal is to inform treatment strategies that improve outcomes, reduce harm, and enhance quality of life for individuals living with severe mental disorders and substance use disorders.

1. Mustonen A, Taipale H, Denissoff A, Ellilä V, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J, Niemelä S. Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis. The British Journal of Psychiatry 2025; 1-7

2. Mustonen A, Niemelä S, Nordström T, Murray GK, Mäki P, Jääskeläinen E, Miettunen J. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. The British Journal of Psychiatry 2018;212(4): 227–233. DOI: https://doi.org/10.1192/bjp.2017.52

3. Denissoff A, Taipale H, Tiihonen J, Di Forti M, Mittendorfer-Rutz E, Tanskanen A, Mustonen A, Niemelä S. Antipsychotic Use and Psychiatric Hospitalization in First-Episode Non-affective Psychosis and Cannabis Use Disorder: A Swedish Nationwide Cohort Study. Schizophrenia Bulletin 2024; sbae034. 10.1093/schbul/sbae034*

4. Mustonen A, Ahokas T, Nordström T, Murray GK, Mäki P, Jääskeläinen E, Heiskala A, McGrath JJ, Scott JG, Miettunen J, Niemelä S. Smokin`hot: adolescent tobacco smoking and the risk of psychosis. Acta Psychiatrica Scandinavica 2018;138(1):5-14. https://doi.org/10.1111/acps.12863

5. Denissoff A, Niemelä S, Hielscher E, Miettunen J, Salom C, Scott JG, Mustonen A. Does Cannabis Use in Adolescence Predict Severe Suicide Attempts or Suicide? Results from a Finnish Birth-Cohort Study. Acta Psychiatrica Scandinavica 2022;145(3):234-243. https://doi.org/10.1111/acps.13384*

6. Mustonen A, Niemelä S, McGrath JJ, Murray GK, Nordström T, Mäki P, Miettunen J, Scott JG. Adolescent inhalant use and psychosis risk – a prospective longitudinal study. Schizophrenia Research 2018;201:360-366. https://doi.org/10.1016/j.schres.2018.05.013*

7. Denissoff A, Mustonen A, Alakokkare AE, Scott JG, Sami M, Miettunen J, and Niemelä S. Is Early Exposure to Cannabis Associated with Bipolar disorder? Results from a Finnish Birth-Cohort Study. Addiction 2022;117:2264– 2272. https://doi.org/10.1111/add.15881*

8. Denissoff A, Mustonen A, Miettunen J, Alakokkare AE, Veijola J, Scott JG, Sami M, Niemelä S. Trajectories of Adolescent Psychotic-like Experiences and Concomitant Cannabis Exposure: Results from a Finnish Birth Cohort Study. Schizophrenia Research 2022;246: 95-102. https://doi.org/10.1016/j.schres.2022.06.014*

9. Mustonen A, Rodriquez A, Scott JG, Vuori M, Hurtig T, Halt AH, Miettunen J, Alakokkare AE, Niemelä S. Attention deficit hyperactivity (ADHD) and oppositional defiant disorder (ODD) symptoms in adolescence and risk of substance use disorders – a general population-based birth cohort study. Acta Psychiatrica Scandinavica 2023; 148(3): 277-287. https://doi.org/10.1111/acps.13588*

10. Scott JG, Matuschka L, Niemelä S, Miettunen J, Emmerson B, Mustonen A. Evidence of a causal relationship between Smoking Tobacco and Schizophrenia Spectrum Disorders. Frontiers in Psychiatry 2018;9:607. https://doi.org/10.3389/fpsyt.2018.00607*